The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 1st 2024
Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.
Dr. Black on Sequencing of Immunotherapy in Bladder Cancer
June 21st 2017Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses sequencing of immunotherapy for patients with bladder cancer.
Dr. Chowdhury on Pembrolizumab Plus Pazopanib in RCC
June 16th 2017Simon Chowdhury, MD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses the combination of pembrolizumab (Keytruda) and pazopanib (Votrient) in patients with renal cell carcinoma (RCC).
Dr. Apolo on Immunotherapy Combinations With Cabozantinib in Genitourinary Tumors
June 13th 2017Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses immunotherapy combinations with cabozantinib (Cometriq) in genitourinary tumors.
Dr. Petrylak on the KEYNOTE-045 Trial for Urothelial Carcinoma
June 9th 2017Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancer, discusses the KEYNOTE-045 trial investigating pembrolizumab (Keytruda) versus physician’s choice of chemotherapy for patients with urothelial carcinoma.
Dr. Choueiri on Avelumab Plus Axitinib in mRCC
June 8th 2017Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses phase I results of axitinib (Inlyta) plus avelumab (Bavencio) for the treatment of patients with metastatic renal cell carcinoma (RCC).
Dr. Apolo on Updated JAVELIN Results of Avelumab in Urothelial Carcinoma
June 4th 2017Andrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses the updated findings of the phase Ib JAVELIN trial exploring avelumab (Bavencio) for the treatment of patients with metastatic urothelial carcinoma.
Dr. Balar on Mature Clinical Results of KEYNOTE-052 in Urothelial Cancer
June 3rd 2017Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the mature clinical trial results and biomarker findings of KEYNOTE-052, first-line pembrolizumab (Keytruda) in patients with cisplatin-ineligible advanced urothelial cancer, during the 2017 ASCO Annual Meeting.
Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer
May 18th 2017Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.
Dr. Black on Combinations with Durvalumab in Bladder Cancer
May 17th 2017Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.
Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer
May 15th 2017Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.
Dr. Siefker-Radtke on FDA Approval of Avelumab in Bladder Cancer
May 10th 2017Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed after platinum-based therapy.
Dr. Hammers on Combination of Vaccines and Immune Checkpoint Inhibitors in RCC
May 5th 2017Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the combination of vaccines and immune checkpoint inhibitors in the treatment of patients with renal cell carcinoma.
Dr. Apolo on Avelumab for Metastatic Urothelial Carcinoma
May 4th 2017Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses avelumab (Bavencio) in patients with metastatic urothelial carcinoma from the phase Ib JAVELIN solid tumor trial.
Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer
May 2nd 2017Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.
FDA Approves Durvalumab for Bladder Cancer
May 1st 2017The FDA has granted an accelerated approval to the PD-L1 inhibitor durvalumab (Imfinzi) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Dr. Drake Discusses Immunotherapy Agents in Bladder Cancer
April 28th 2017Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.
Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer
April 18th 2017Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.
Dr. Tagawa Discusses the Development of Immunotherapy in Urothelial Cancer
April 14th 2017Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.